Study Suggests Urine NGAL Biomarker May Help Predict Delayed Graft Function
DGF occurs when a transplanted kidney does not function immediately. It is a common complication after kidney transplants, and in some reports, the incidence is as high as 40 percent. DGF is an increasing problem as more kidneys coming from expanded criteria donors are accepted for transplantation.
The aim of the study, led by Maria Hollmen, M.D., Helsinki University Hospital, was to examine how serial urine NGAL (neutrophil gelatinase-associated lipocalin) concentrations change over time following kidney transplants and whether urine concentrations of NGAL can predict the onset of delayed graft function or prolonged delayed graft function.
DGF and prolonged DGF (14 days or longer) can cause acute organ rejection, require patients to undergo dialysis, prolong post-transplant hospital stays, and increase post-operative care costs. According to the study's authors, there is an unmet medical need for an effective test to help predict delayed graft function soon after transplantation, which could help in developing therapeutic interventions to prevent DGF.
"Day one urinary NGAL predicted DGF even when it was not clinically expected early on, and importantly, it predicted prolonged DGF that led to worse graft survival," according to Dr. Hollmen.
One-hundred-and-seventy-six renal transplant patients were evaluated in the study. Urine samples were collected before transplantation and for several days afterward. Seventy patients had DGF and 26 of them were prolonged.
The patients who developed DGF had a significantly slower decrease in urinary NGAL compared to those without DGF. Urine NGAL levels measured a day following transplant predicted prolonged DGF, which had significantly worse one-year graft survival (73 percent) compared with shorter DGF (100 percent).
In the study, the researchers concluded that urine NGAL measurements can predict prolonged DGF and identify patients with severe kidney injury and inferior long-term organ survival. They added that the test also provides a simple method to quantify recovery from kidney injury.
Most read news
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.